Philippe Merle
Professor
Lyon College
faculty
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Dr. Philippe Merle is a hepato-gastroenterologist and digestive oncologist who leads clinical research on hepatocellular carcinoma at the University Hospital of Lyon, France, and is a Professor at Lyon College. His work is centered on advancing the treatment and improving the prognosis of hepatocellular carcinoma, alongside broader interests in liver disease diagnosis and management, hepatitis B virus, and pancreatic and hepatic oncology. Dr. Merle's research extends to colorectal cancer treatments and studies. He has recently contributed to several clinical trials evaluating novel therapeutic combinations for advanced hepatocellular carcinoma, including studies on atezolizumab plus bevacizumab and cabozantinib plus atezolizumab, with the most recent publication in 2025. His research focuses on the treatment of hepatocellular carcinoma.
Metrics
- h-index: 58
- Publications: 420
- Citations: 29,857
Selected Publications
- Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies (2025) DOI
- Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study (2024) DOI
- Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150 (2024) DOI
- International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI). (2024) DOI
- Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma (2024) DOI
- Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study (2024) DOI
- Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study. (2024) DOI
- Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023) DOI
- Prognostic factors and survival prediction in hepatocellular carcinoma: development and validation of a novel nomogram based on the SEER database (2023) DOI
- Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting (2023) DOI
- Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy (2023) DOI
- Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry (2023) DOI
- Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial (2023) DOI
- Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial (2023) DOI
- TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial (2023) DOI
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics